Abstract
Background The association between cardiovascular disease (CVD) and selected psychiatric disorders has frequently been suggested while inadequate control of familial factors and comorbidities has halted causal inferences.
Methods We identified 869 056 patients newly diagnosed with CVD from 1987 to 2016 in Sweden while no history of psychiatric disorders, and 910 178 full siblings of these patients and 10 individually age- and sex-matched unrelated population controls (N=8 690 560). Adjusting for multiple comorbid conditions, we used flexible parametric models and Cox regression to estimate the association of CVD with risk of all subsequent psychiatric disorders, comparing rates of first incident psychiatric disorder among CVD patients with rates among unaffected full siblings and population controls.
Results The median age at diagnosis was 60 years for patients with cardiovascular disease and 59.2% were male. During up to thirty years of follow-up, the crude incidence rates of psychiatric disorder were 7.1, 4.6 and 4.0 per 1000 person-years for patients with cardiovascular disease, their siblings and population controls. In the sibling comparison, we observed an increased risk of psychiatric disorder during the first year after cardiovascular diagnosis (hazard ratio [HR], 2.74; 95% confidence interval [CI], 2.62-2.87) and thereafter (1.45; 95% CI, 1.42-1.48). Increased risks were observed for all types of psychiatric disorders and among all diagnoses of cardiovascular disease. We observed similar associations in the population comparison. Cardiovascular patients who developed a comorbid psychiatric disorder during the first year after diagnosis were at increased risk of subsequent cardiovascular death compared to patients without such comorbidity (HR 1.55; 95% CI 1.44-1.67).
Conclusions Patients diagnosed with cardiovascular disease are at an elevated risk for subsequent psychiatric disorders independent of familial factors and comorbid conditions. Cardiovascular patients with comorbid psychiatric disorders are at increased risk of cardiovascular mortality suggesting that surveillance and treatment of psychiatric comorbidities should be considered as an integral part of clinical management of newly diagnosed patients with cardiovascular disease.
Funding this work was supported by the EU Horizon 2020 Research and Innovation Action Grant (CoMorMent, Grant nr. 847776 to UV, PFS and FF), Grant of Excellence, Icelandic Research Fund (grant no. 163362-051 to UV), ERC Consolidator Grant (StressGene, grant no: 726413 to UV), Swedish Research Council (Vetenskapsrådet, award D0886501 to PFS) and US NIMH R01 MH123724 (to PFS).
Introduction
Being diagnosed and living with a major life-threatening disease is stressful and associated with multiple biologic processes that combined may contribute to the development of psychiatric disorders. It is for instance firmly demonstrated that a cancer diagnosis is associated with a rapid rise of psychiatric disorders1 and self-inflicted injury,2 which further is associated with a compromised cancer specific survival.3 Psychiatric comorbidities have also been reported among patients with cardiovascular disease (CVD), e.g. after stroke,4 heart failure,5 and myocardial infarction.6,7 with indications of elevated risk of overall mortality.8,9 Yet, evidence on the association between CVD and subsequent development of psychiatric disorders is still limited as previous research has mainly relied on selected patient populations instead of complete follow-up of general population as well as limited control of reverse causality and important confounding factors, e.g. familial factors and comorbidities.10–12
We thoroughly searched the existing literature of investigating the association between CVD and clinically confirmed psychiatric disorders or psychiatric symptoms. After excluding most studies with either cross-sectional or retrospective designs, we only found 12 prospective cohort studies investigating the risk of selected psychiatric disorders following diagnosis of cardiovascular disease (summarized in Table S1, Supplementary Appendix). While these prospective studies suggest a positive association between hypertension, heart disease, and stroke with depressive symptoms11,13–15 and stress-related disorders,16 they were limited to elderly populations,17,18 and using self-reported ascertainment of psychiatric outcomes.17,18 Only few of these studies addressed incident or first diagnosed psychiatric disorders among patients with CVD, e.g. exlcuding patients with history of psychiatric disorders, and no study addressed the issue of familial confounding. Indeed, genetic correlation between these two complex diseases have recently been documented 19–21 as well as the importance of early life environment for the development of both cardiovascular disease22 and psychiatric disorders.23 It is therefore unknown whether the reported association between CVD and psychiatric disorder can be attributed to unmeasured confounding shared within families.19–21 Thus, a comprehensive evaluation of the association between all CVDs and risk of any incident psychiatric disorder, addressing the abovementioned shortcomings, is warranted.
With up to thirty years of follow-up and with nationwide complete information on family links in Sweden, we aimed to comprehensively investigate the association between CVD diagnosed in specialist care and subsequent risk of incident psychiatric disorders while accounting for familial factors through a sibling comparison. We further aimed to estimate the potential role of psychiatric comorbidity in cardiovascular mortality among patients with CVD.
Materials and Methods
Study Design
The Swedish Patient Register contains national information on inpatient care with complete coverage since 1987 and outpatient specialized care since 2001.25 The Swedish Multi-Generation Register includes nearly complete familial information for Swedish residents born since 1932.26 Using personal identification numbers assigned to all Swedish residents, we identified all individuals born in Sweden after 1932 who received a first diagnosis of any CVD that attended in inpatient or outpatient specialized care between 1 January 1987 and 31 December 2016 (N=986 726). Patients diagnosed with CVD before age 5 (N=6 091, probable congenital heart disease) or with a history of any psychiatric disorder before the diagnosis of CVD (N=111 579) were excluded, leaving 869 056 patients in the analysis (Fig S1, Supplementary Appendix). Date of first CVD diagnosis was used as the index date for the exposed patients.
Through the Multi-Generation Register, we identified all full siblings of patients with CVD (58.6% of all CVD patients) who were alive and free of CVD and psychiatric disorder at the time when their affected sibling was diagnosed (N=910 178). In addition, for each patient with CVD, we randomly selected 10 age-and sex-matched individuals from the general population who were free of CVD or psychiatric disorder when the index patient was diagnosed (N=8 690 560). The date of CVD diagnosis for the index patient was used as the index date for their unaffected siblings and matched population controls.
All study participants were followed from the index date until first diagnosis of any psychiatric disorder, death, emigration, first diagnosis of CVD (for unaffected siblings and matched population controls), or the end of the study period (31 December 2016), whichever occurred first.
Ascertainment of Cardiovascular Disease and Psychiatric Disorder
We defined CVD as any first inpatient or outpatient hospital visit with CVD as the primary diagnosis from the Swedish Patient Register. Incident psychiatric disorder was defined as any first inpatient or outpatient hospital visit with psychiatric disorder as the primary diagnosis. We used the 9th and 10th Swedish revisions of the International Classification of Diseases (ICD-9 and 10) codes to identify CVD and psychiatric disorders and their subtypes (Table S2, Supplementary Appendix). In line with previous study,27 we classified CVD as ischemic heart disease, cerebrovascular disease, emboli/thrombosis, hypertensive disease, heart failure, and arrhythmia/conduction disorder. We classified psychiatric disorders as non-affective psychotic disorders, affective psychotic disorders, alcohol or drug misuse, mood disorders excluding psychotic symptoms, anxiety and stress-related disorders, eating disorders, and personality disorders.28
Covariates
We extracted socioeconomic information for each participant, including educational level, individualized family income and cohabitation status, from the Longitudinal Integration Database for Health Insurance and Labor Market.29 Missing information on socioeconomic status was categorized as unknown or missing group. A history of somatic diseases was defined as having any of the following conditions before the index date: chronic pulmonary disease, connective tissue disease, diabetes, renal diseases, liver disease, ulcer diseases, malignancies, and HIV infection/AIDS (Table S2, Supplementary Appendix). We defined a family history of psychiatric disorders as a diagnosis of any psychiatric disorder among biological parents and full siblings of the study participants before the index date according to the Swedish Patient Register.
Statistical Analysis
We used flexible parametric survival models to estimate the time-varying association between CVD and subsequent risk of incident psychiatric disorders,30 by comparing the rates of incident psychiatric disorders in CVD patients with the corresponding rates in their unaffected full siblings and matched population controls. As we observed a marked risk increase of psychiatric disorders immediately following the CVD diagnosis, we separately assessed the association within one year of CVD diagnosis and beyond one year. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were derived from stratified Cox regression models, using time since the index date as the underlying time scale. We estimated HRs for any psychiatric disorder and categories of psychiatric disorders. We performed subgroup analyses by sex, age at index date (<50, 50-60, or >60 years), age at follow-up (<60 or ≥60 years), calendar year at index date (1987-1996, 1997-2006, or 2007-2016), history of somatic diseases (no or yes), and family history of psychiatric disorder (no or yes). In the sibling comparison, all Cox models were stratified by sibling sets and adjusted for sex, birth year, educational level, individualized family income, cohabitation status, and history of somatic diseases. In the population comparison, all Cox models were stratified by the matching variables birth year and sex and adjusted for all abovementioned covariates plus family history of psychiatric disorder.
To study the impact of additional cardiovascular comorbidity (i.e., patients with another type of CVD after diagnosis of the first CVD), we analyzed the association by presence or absence of cardiovascular comorbidity after the index date according to the type of first CVD. This analysis was restricted to follow-up beyond one year to focus on patients who survived their first CVD to be able to receive the diagnosis of another CVD. As a patient with CVD might have different types of CVD, we identified all diagnoses of CVD during follow-up and considered CVD comorbidity as a time-varying variable through splitting the person-time according to each diagnosis.
Because the Swedish Patient Register includes only information related to specialist care, we might have misclassified patients with psychiatric symptoms who were only attended by primary care. In a sensitivity analysis, we excluded also individuals with prescribed use of psychotropic drugs before the index date (ascertained from the Swedish Prescribed Drug Register including information on all prescribed medication use in Sweden since July 2005), and followed the remaining participants during 2006-2016. Use of psychotropic drugs during follow-up was also considered as having psychiatric disorder in this analysis.
To study rate of cardiovascular mortality (ascertained from the Swedish Causes of Death Register) in relation to psychiatric comorbidities after CVD diagnosis, we plotted Kaplan-Meier survival curves beyond the first year of follow-up for CVD patients with or without a diagnosis of psychiatric disorder during the first year of follow-up, separately. In addition to this 1-year time window, we also studied six months or two years since CVD diagnosis, to assess the robustness of these survival curves. We calculated the HRs of cardiovascular mortality for these two groups of patients using Cox regression model.
Analyses were performed in STATA 17.0 (StataCorp LP). All tests were two sided and P<0.05 was used as statistically level of significance. The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Results
The median age at index date was 60 years for CVD patients and 55 years for their unaffected full siblings (Table 1). 59.2% of the CVD patients and 48.4% of their unaffected siblings were male. CVD patients were more likely to have a history of somatic diseases than their unaffected siblings and matched population controls (15.6% vs. 8.8% and 11.0%). The most common diagnoses among the CVD patients were ischemic heart diseases (24.5%), arrhythmia/conduction disorders (24.2%), and hypertensive diseases (17.3%). The majority of the CVD patients had only one CVD diagnosis (without additional CVD comorbidities) during follow-up (69.7%).
During up to thirty years of follow-up, the crude incidence rates of psychiatric disorder were 7.1, 4.6 and 4.0 per 1000 person-years among CVD patients, their unaffected full siblings, and matched population controls, respectively (Table S3, Supplementary Appendix). Compared with unaffected siblings, CVD patients showed an increased risk of incident psychiatric disorder, especially immediately after diagnosis (Fig 1). The risk declined rapidly within the first few months after diagnosis and decreased gradually thereafter: the HR was 2.74 (95% CI 2.62 to 2.87) within first year and 1.45 (95% CI 1.42 to 1.48) beyond first year (Table S4, Supplementary Appendix). The risk increment was noted in all types of psychiatric disorders within and beyond first year of follow-up (Fig 2). Overall, the observed risk increase was similar in sibling and population comparisons, although the HR of non-affective psychotic disorders beyond one year of CVD diagnosis was smaller in the sibling comparison than in the population comparison. During the entire follow-up, we found similar positive associations across sex, age at index date, age at follow-up, history of somatic diseases and family history of psychiatric disorders (Table S3). A greater risk increment was observed in recent calendar years than earlier years.
We found an increased risk of incident psychiatric disorder among all groups of CVD patients, with the most marked risk increase observed among patients with cerebrovascular disease and heart failure (Fig 3). A greater risk increase of incident psychiatric disorder was noted among CVD patients with additional cardiovascular comorbidities beyond one year of first CVD diagnosis compared with CVD patients without such comorbidities, except among those with heart failure (Fig S2, Supplementary Appendix). We found a similar positive association between CVD and risk of incident psychiatric disorder, when including use of psychotropic drugs as a definition of psychiatric disorder (Table S5, Supplementary Appendix).
CVD patients diagnosed with subsequent psychiatric disorder showed a reduced CVD-specific survival compared with patients without such diagnosis (Fig 4, and Supplementary Appendix Fig S3 and S4). The HR of cardiovascular death was 1.55 (95% CI 1.44 to 1.67) when comparing CVD patients with a diagnosis of psychiatric disorder to patients without such diagnosis (mortality rate, 9.2 and 7.1 per 1 000 person-years, respectively).
Discussion
Our large population-based sibling-controlled cohort study including all patients diagnosed with their first CVD between 1987 and 2016 in Sweden, their unaffected full siblings, as well as a set of randomly selected unaffected population controls reveals a robust association between CVD and subsequent risk of incident psychiatric disorder. We found that patients with CVD were at elevated risk of various types of psychiatric disorders, independent of confounding factors shared within families and history of somatic diseases. The risk increment was greatest during the year after CVD diagnosis, indicating an opportunity for clinical surveillance in a high-risk time window. Further, an occurrence of psychiatric comorbidity after CVD diagnosis was associated with an approximately 55% increased risk of subsequent death from cardiovascular causes. This finding further underscores the importance of surveillance and, if needed, treatment of psychiatric comorbidities among newly diagnosed CVD patients.
Strengths and Limitations
The strengths of our study include its large sample size of the entire Swedish nation and the prospective study design with sibling comparison that significantly alleviates concerns of familial confounding from shared genetic and early-life environmental factors between siblings. The Swedish population and health registers provide the opportunity to obtain complete follow-up as well as prospectively and independently collected information on disease identification, minimizing the risk of selection and information biases. The large sample size of our study further enables detailed subgroup analyses by types of CVD, types of psychiatric disorders, and patient characteristics.
Some limitations need to be acknowledged. First, we identified patients with CVD and psychiatric disorder through inpatient or outpatient hospital visit. The later inclusion of outpatient records in the Swedish Patient Register may lead to underestimation of the actual numbers of patients with CVD and psychiatric disorder, especially those with relatively milder symptoms. Second, we missed individuals attended in primary care, which may underestimate the proportion of individuals with history of psychiatric problems at study entry. To alleviate such concerns, we additionally considered the use of prescribed psychotropic drugs and found similar results. Further, patients with CVD have an established contact with health care and may therefore be more likely than others to be diagnosed with psychiatric disorder. Although such surveillance bias may to some extent explain the increased risks during the first few months after CVD diagnosis, it is unlikely that the risk elevation during the entire follow-up is attributed to such bias. Finally, we could not directly control for lifestyle factors (e.g., smoking, diet, and physical exercise) and therefore cannot exclude the possibility of residual confounding not fully controlled for in the sibling comparison.
Comparison with other studies
Our findings are consistent with the existing literature suggesting a positive association between CVD and different types of psychiatric disorders. In previous studies, an increased risk of depression13–15 and anxiety11 was noted after diagnosis of stroke,11,13–15 hypertension,17 coronary artery disease31 and atrial fibrillation.32 Such risk elevations has been suggested to be persistent over time,10,33,34 and, in parallel with our findings, associated with compromised survival.8,35,36 However, the evidence from prospective cohort studies with a long and complete follow-up as well as with a thorough control of confounding factors and comorbid conditions has, up to this point, been limited. Our study therefore complements previous findings revealing a positive association between a broader range of CVDs and subsequent risk of incident psychiatric disorder, using a large cohort with control of various confounding factors. We found the association to be robust both in sibling and population comparisons, and after additional adjustment for various comorbidities including other additional CVDs, indicating that the association is unlikely explained by shared familial factors and various comorbidities. We showed that CVD patients with psychiatric comorbidity was associated with an increased risk of subsequent CVD death, highlighting the importance of surveillance and prevention on psychiatric comorbidities for those newly diagnosed CVD patients.
The association between CVD and psychiatric disorders was noted both in men and women, across all age groups and calendar periods, as well as among individuals with or without a history of somatic diseases and family history of psychiatric disorders. Previous studies have indicated that major depression was more commonly recognized among individuals with multimorbidity (more than one CVD diagnosis) than those with only one condition.37 In our study, about 30% of the CVD patients developed one or more cardiovascular comorbidities during follow-up, and a higher risk of psychiatric disorder was indeed noted among patients with multiple CVD diagnoses. A compromised survival from CVD cause was indeed observed among most patients with common types of first CVD diagnosis and comorbid with psychiatric disorder.
Potential mechanisms
The pathophysiological mechanisms linking CVD and psychiatric disorders are complex and not well understood, and may vary with specific diagnoses of CVD and psychiatric disorders. The highly increased risk noted immediately after CVD diagnosis may indicate a direct impact of stress reaction of being diagnosed with a life-threatening disease.38 In addition, it has been proposed that biological alterations in the cardiovascular system to a severe stress response may increase the risk of various psychiatric disorders.39 For example, cardiovascular risk factors including hypercoagulability, dyslipidemia, and an impaired immune response have been associated with impaired psychological health.39 Some biological changes in patients with coronary heart disease (e.g., decreased heart rate variability, increased arterial stiffness, and endothelial dysfunction) have been observed in patients with depressive and anxiety disorders.40–42 Chronic inflammation may induce the development of atherosclerosis and arterial thrombosis, and elevation in inflammatory biomarkers (i.e., IL-6 and C-reactive protein) has been reported in various psychiatric disorders including post-traumatic stress disorder and major depression.43–45 Other behavioral and psychosocial factors may as well interact with these pathways and need to be understood further.
Conclusions
Using a large population-based sibling-controlled cohort with up to thirty years of follow-up, we demonstrate that patients with CVD have an increased risk of first-diagnosed psychiatric disorder, independent of familial background, history of somatic diseases, and other cardiovascular comorbidities. Our study further indicates an impact of psychiatric comorbidities on cardiovascular mortality among patients with CVD, motivating increased surveillance of psychiatric comorbidity among newly diagnosed patients with CVD.
Data Availability
Data analyses were performed in STATA 17.0 (StataCorp LP). STATA script used in the primary analyses has been made available as supplementary appendix. Aggregated data used for generating figures are available in supplementary appendix. The original data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. The authors are not able to make the dataset publicly available according to the Public Access to Information and Secrecy Act in Sweden. Any researchers (including international researchers) interested in accessing the data can send request to the authorities for data application by: 1) apply for ethical approval from local ethical review board; 2) contact the Swedish National Board of Health and Welfare (https://bestalladata.socialstyrelsen.se/, email: registerservice@socialstyrelsen.se) and/or Statistics Sweden (https://www.scb.se/vara-tjanster/bestall-data-och-statistik/, email: scb@scb.se) with the ethical approval and submit a formal application for access to register data. The same contacts can be used for detailed information about how to apply for access to register data for research purposes."
Competing interest
The authors declare that there is no conflict of interest.
Author Contributions
Drs Shen, Fang, and Valdimarsdóttir had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data.
Concept and design: Shen, Fang, and Valdimarsdóttir.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Shen, Fang, and Valdimarsdóttir.
Statistical analysis: Shen, Song, Fang, and Valdimarsdóttir.
Obtained funding: Fang, Valdimarsdóttir and Sullivan.
Administrative, technical, or material support: Shen, Fang, Valdimarsdóttir, Yu and Ye.
Supervision: Fang and Valdimarsdóttir.
Role of the Funder
The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, or approval of the manuscript; and decision to submit the manuscript for publication.
Ethical approval
The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32). Informed consent to each participant was waived by Swedish law in nationwide registry data.
Data availability statement
Data analyses were performed in STATA 17.0 (StataCorp LP). STATA script used in the primary analyses has been made available as supplementary appendix. Aggregated data used for generating figures are available in supplementary appendix. The original data used in this study are owned by the Swedish National Board of Health and Welfare and Statistics Sweden. The authors are not able to make the dataset publicly available according to the Public Access to Information and Secrecy Act in Sweden. Any researchers (including international researchers) interested in accessing the data can send request to the authorities for data application by: 1) apply for ethical approval from local ethical review board; 2) contact the Swedish National Board of Health and Welfare (https://bestalladata.socialstyrelsen.se/, email: registerservice{at}socialstyrelsen.se) and/or Statistics Sweden (https://www.scb.se/vara-tjanster/bestall-data-och-statistik/, email: scb{at}scb.se) with the ethical approval and submit a formal application for access to register data. The same contacts can be used for detailed information about how to apply for access to register data for research purposes.”
Transparency declaration
UV affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.